$18.24
2.07% today
Nasdaq, Dec 04, 09:19 pm CET

10x Genomics Inc - Ordinary Shares - Class A Stock price

$17.87
+4.17 30.44% 1M
+8.76 96.16% 6M
+3.51 24.44% YTD
+2.05 12.96% 1Y
-18.70 51.13% 3Y
-127.35 87.69% 5Y
-34.88 66.12% 10Y
-34.88 66.12% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
-0.07 0.39%

New AI Insights on 10x Genomics Inc - Ordinary Shares - Class A Insights AI Insights on 10x Genomics Inc - Ordinary Shares - Class A

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$1.8b
Net debt
positive
Cash
$482.1m
Shares outstanding
126.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.5 | 3.6
EV/Sales
2.8 | 2.9
EV/FCF
21.8
P/B
2.9
Financial Health
Equity Ratio
77.3%
Return on Equity
-25.7%
ROCE
-15.3%
ROIC
-30.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$641.8m | $623.4m
EBITDA
$-105.6m | $-76.5m
EBIT
$-134.5m | $-81.7m
Net Income
$-76.3m | $-77.5m
Free Cash Flow
$81.7m
Growth (TTM | estimate)
Revenue
1.9% | 2.1%
EBITDA
18.0% | 51.1%
EBIT
21.6% | 57.5%
Net Income
58.2% | 57.6%
Free Cash Flow
226.1%
Margin (TTM | estimate)
Gross
68.9%
EBITDA
-16.5% | -12.3%
EBIT
-21.0%
Net
-11.9% | -12.4%
Free Cash Flow
12.7%
More
EPS
$-0.6
FCF per Share
$0.6
Short interest
19.5%
Employees
1k
Rev per Employee
$470.0k
Show more

Is 10x Genomics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

10x Genomics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

10x Buy
43%
13x Hold
57%

Analyst Opinions

23 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

Buy
43%
Hold
57%

Financial data from 10x Genomics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
642 642
2% 2%
100%
- Direct Costs 200 200
5% 5%
31%
442 442
5% 5%
69%
- Selling and Administrative Expenses 331 331
0% 0%
52%
- Research and Development Expense 246 246
6% 6%
38%
-106 -106
18% 18%
-16%
- Depreciation and Amortization 29 29
33% 33%
4%
EBIT (Operating Income) EBIT -134 -134
22% 22%
-21%
Net Profit -76 -76
58% 58%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about 10x Genomics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

10x Genomics Inc - Ordinary Shares - Class A Stock News

Neutral
PRNewsWire
16 days ago
Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region PLEASANTON, Calif. and SYDNEY , Nov. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc.
Neutral
PRNewsWire
23 days ago
PLEASANTON, Calif. , Nov. 11, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research Healthcare Conference 2025 on Tuesday, November 18, at 11:20 a.m.
Neutral
Seeking Alpha
28 days ago
10x Genomics, Inc. ( TXG ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Adam Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Madeline Mollman Puneet Souda - Leerink Partners LLC, Research Division...
More 10x Genomics Inc - Ordinary Shares - Class A News

Company Profile

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

Head office United States
CEO Serge Saxonov
Employees 1,306
Founded 2012
Website www.10xgenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today